Skip to main content
Premium Trial:

Request an Annual Quote

ADx NeuroSciences, Quanterix Ink Deal to Develop Blood-Based Concussion Test

NEW YORK (GenomeWeb) – ADx NeuroSciences and Quanterix announced today that they have signed a deal to collaborate on a blood-based diagnostic test for concussion and traumatic brain injury.

The firms, who previously collaborated on the development of a blood-based diagnostic for Alzheimer's disease, said the new test will measure levels of the tau protein in a person's blood as tau leaks from the brain into the bloodstream following head trauma or injury. The companies will merge ADx's Tau antibodies with Quanterix's ultrasensitive single-molecule array platform, resulting in a highly sensitive test that can detect the very small amounts of tau in the blood following an injury.

Further terms of the deal were not disclosed.

"We are very pleased with this long-term collaboration with Quanterix," said ADx CEO Koen Dewaele in a statement. "It is also a perfect business case on how the market potential of one product can be expanded into a new market: from Alzheimer's disease to traumatic brain injury."

In July 2015, Quanterix received a $500,000 grant from GE and the National Football League to address the diagnosis and prognosis of brain trauma.

ADx further announced today that it has concluded its third financing round, and received a capital increase of an undisclosed amount from two new individual private investors and existing shareholders. The firm will use the additional capital to develop biomarkers for Alzheimer's and Parkinson's disease, and research other neurodegenerative disorders such as ALS. Last week, Quanterix also announced that it had raised additional funding, completing a Series D round for $46 million from new and existing investors.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.